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A B S T R A C T
We previously reported the safety and eﬃcacy of low dose BaP [Bezaﬁbrate (Bez) and Medroxyprogesterone
acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This
study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absence of haematological
toxicity allowed continuous daily administration. Similarly a previous trial in endemic Burkitt lymphoma de-
monstrated anti-B cell lymphoma activity of low and high dose BaP again in the absence of toxicity.
We conducted a study to further evaluate the safety and activity of high dose BaP therapy in adults with AML
(and high risk Myelodysplastic Syndromes (MDS)), chronic lymphocytic leukaemia (CLL) or B-cell Non-Hodgkin
Lymphoma (BHNL). Eighteen patients were recruited to the study over 20 months, 16 AML/MDS, 1 CLL, and 1
BNHL. Although MPA was well tolerated throughout the study, only 2 patients were able to tolerate Bez
treatment for their whole trial duration, indicating that Bez escalation is not feasible in the setting of adult AML/
MDS. Thus there has been no obvious beneﬁt in improved haemopoiesis or overt anti-leukaemia activity from
the attempts to escalate BaP dose over previous published studies. Since current therapeutic options in MDS are
restricted it may be now of value to continue to evaluate low dose BaP based approaches in low risk MDS rather
than AML/high risk MDS. Furthermore, screening of low dose BaP against libraries of other already available
dugs may identify an addition to BaP that augments the anti-neoplastic eﬃcacy without signiﬁcant toxicity.
1. Introduction
1.1. More than half of all patients with Acute Myeloid leukaemia (AML)
and substantial proportions of
Chronic Lymphocytic Leukaemia (CLL) and B-cell Non-Hodgkins
Lymphoma (BNHL) patients either present, or reach a point in their
disease, where anti-cancer therapy is inappropriate because it is no
longer eﬀective or its toxicity cannot be tolerated, usually due to age
and inﬁrmity. At this stage of their disease the loss of normal haemo-
poiesis creates life-threatening deﬁcits of erythrocytes, platelets, and
neutrophils that are managed using blood and platelet transfusion and
aggressive treatment of neutropenic infections. Other than palliative
treatment with prednisolone in B cell malignancy and hydroxyurea to
control rising myeloid blast counts, there is no available treatment and
survival is poor.
We previously reported the safety and eﬃcacy of low dose BaP
[Bezaﬁbrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20
AML patients for whom chemotherapy was not an option
(ISRCTN50635541) [1]. The study provided evidence of both anti-AML
activity and improved haemopoiesis; absence of haematological toxi-
city allowed continuous daily administration.
Subsequent in vitro studies indicated that Bez doses 12x and MPA
doses 2.5x that used in the above study (termed hereafter as full dose
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BaP), would likely have substantially greater eﬃcacy against AML [2].
We have also reported the safety and eﬃcacy of BaP in primary re-
sistant and relapsed Burkitt lymphoma in Malawi (ISRCTN34303497).
33 children received low dose BaP, 28 intermediate dose and 34 full
dose without evidence of toxicity, and with evidence of anti-lymphoma
activity most eﬀective at the full dose [3].
This current study was therefore designed to further evaluate the
safety, compliance (feasibility of delivery) and activity of full-dose BaP
in adults with AML (and high risk MDS), CLL or BNHL.
2. Methods
Enrolment of patients took place between October 2012 and June
2014. As this was a pilot study, it did not involve any formal statistical
hypothesis testing. Whilst anticipating recruiting 20 patients to each of
the 3 diseases, the trial was terminated at a total of 18 patients (16 with
AML/MDS (RAEB2) and 1 each of CLL and BNHL) due to slow re-
cruitment and time spent amending the protocol dosing. Patient char-
acteristics of the AML/MDS (RAEB2) cohort are given in Table 1.
The initial protocols used for this study were a starting dose of Bez
(modiﬁed release) of 2400mg twice daily in patients with an eGFR
≥60ml/min. Where patients had an eGFR of 40–59.9ml/min, the
starting dose of Bez (standard release) was 1200mg twice daily. All
patients received 1000mg MPA daily. All analyses were descriptive,
with no statistical testing.
Outcomes: safety, compliance, haematological response and sur-
vival [4].
3. Results
3.1. AML/MDS (RAEB 2) cohort
MPA was well tolerated throughout the study with 9/16 patients
taking MPA continuously throughout the trial. 14/16 patients took
MPA for more than 80% of the trial duration. One of the 16 patients did
not start treatment due to poor health. There were no occasions where
the patient stopped MPA but not Bez, although patients frequently took
MPA alone.
Of the four patients recruited to the initial protocols, three patients
took the full dose of modiﬁed release Bez (4800mg daily) but none for
more than two weeks. The fourth patient commenced on standard re-
lease Bez at the full dose (2400mg daily) but discontinued after 5.9
weeks. The protocol was subsequently amended to reduce the starting
dose to 1600mg daily of modiﬁed release Bez or 800mg daily standard
release Bez, with the ability to dose escalate up to 4800mg daily of
modiﬁed release Bez or 2400mg daily standard release Bez.
12 patients were recruited onto this amended protocol; of those that
had more than four weeks of treatment, four had a mode dose of
1600mg and one had a mode dose of 3200mg (the mode dose was
taken in these patients for a range of 3–7 weeks). Only 2 patients on the
amended protocol were able to take Bez for their whole trial duration
which was 5.4 weeks for one patient and 8.6 weeks for another. All
other patients had at least one period where their Bez had to be in-
terrupted. No patient was able to escalate to the full dose of BaP
therapy.
Interruptions or changes in Bez doses were largely due to either a
rise in Creatinine Kinase (CK) or a fall in eGFR. In one patient receiving
4800mg daily of Bez, treatment had to be stopped because of myalgia
and an elevated CK indicative of rhabdomyolysis. In a further ﬁve pa-
tients, Bez was temporarily stopped because of elevations of CK (in two
patients associated with myalgia and one with oedema); all patients
recommenced lower doses of Bez. All patients experienced their ﬁrst
rise in CK within two weeks of starting modiﬁed release Bez at a dose of
1600mg.
Bez is contraindicated in patients with an eGFR<40ml/min and if
the eGFR drops below 60ml/min, patients must change from modiﬁed
Bez to standard release Bez. In six patients (10 occasions), reductions in
eGFR required a change in the dose of Bez and in ﬁve of these patients
(7 occasions) this also required a change in formulation.
Compliance was assessed using patient diaries against dose pre-
scribed. Where a patient diary was unavailable it was assumed that the
patient was non-compliant for the duration of the missing diary. The
median (IQR) compliance for Bez for all patients was 75% (68–96) and
75% (70–91) for MPA. The median (IQR) compliance for Bez for pa-
tients with all patient diaries returned was 95% (79–100) and 94%
(84–100) for MPA. The most common reasons for non-compliance were
diﬃculty in taking the large number of tablets required to deliver the
full dose, hospital admissions and nausea.
Toxicities were also reported at higher grades and rates than in
previous BaP studies [1,3] with 12 and 6 occurrences of grade 3 and 4
toxicities respectively assessed as being at least possibly related to BaP.
The majority of these events fell into the ‘Investigations’ category. The
median survival for this cohort of patients was 10.6 weeks (95% CI: 6.6,
20.6).
Seven patients took trial medication for> 8 weeks and three
Table 1
Patient Characteristics (n=16 unless stated otherwise).
Median (IQR) age (years) 75.3 (67.9–77.8)
Sex
Male 11 (68.7%)
Female 5 (31.3%)
ECOG performance status
0 4 (25.0%)
1 7 (43.7%)
2 2 (12.5%)
3 2 (12.5%)
Missing 1
Diagnosis
MDS (RAEB2) 2 (12.5%)
AML transformed from MDS 5 (31.3%)
Other secondary AML 1 (6.3%)
Primary AML 7 (43.8%)
Missing 1
Median (IQR) time from original diagnosis to trial entry
(weeks)
13.3 (3.6–75.0)
Missing 1
Disease status
Previously untreated 8 (50.0%)
Relapsed 5 (31.3%)
Refractory 2 (12.5%)
Missing 1
Transfusion dependent (TD) patients
Red blood cell 9 (56.3%)
Platelet 4 (25.0%)
Missing 1
Haemoglobin in patients that are not red blood cell TD (n=6)
Median (IQR) Haemoglobin (g/dL) 10.4 (9.4–12.0)
Platelets in patients that are not platelet TD (n=11)
>100×109/L 4 (36.4%)
20–100×109/L 5 (45.4%)
<20×109/L 2 (18.2%)
Median counts (IQR)
White cell count (x109/L) 2.2 (1.4–7.0)
Missing 1
Neutrophils (x109/L)
≥1×109/L 4 (25.0%)
<1×109/L 10 (62.5%)
Not known 1 (6.3%)
Missing 1
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for> 12 weeks; one had a haematological response (erythroid and
platelets). Median survival was 10.6 weeks (95% CI: 6.6, 20.6).
3.2. CLL and BNHL cohorts
Only 1 patient was recruited into each of these cohorts. The BNHL
patient (male, 71.9 years, ECOG=0, relapsed disease) received 5
weeks of standard release Bez and 4.9 weeks of modiﬁed release Bez,
MPA was continued throughout. BaP was discontinued at 18 weeks due
to disease progression. The CLL patient (male, 81.4 years, ECOG=1,
relapsed disease) withdrew from the trial after 5 days due to toxicity.
The time from registration to death for the BNHL patient was 28.0
weeks and 27.7 weeks for the CLL patient.
4. Discussion
Although high dose BaP was tolerated and eﬃcacious in children
with endemic Burkett's lymphoma [3], this elderly patient group have
not tolerated high dose Bez. This intolerance reﬂects multiple reasons
including reduced and ﬂuctuating renal function and a propensity to
develop myalgia with elevated CK. Therefore, future trials should
consider only recruiting patients with an eGFR greater than 50ml/min
and using only the standard release formulation of Bez to improve
duration of treatment.
Whilst diﬃcult to draw conclusions from this study due to the
challenges in patients remaining on treatment with Bez, there has been
no obvious beneﬁt in improved haemopoiesis or overt anti-leukaemia
activity from the attempts to escalate BaP dose over the previous
published study [1]. No conclusions about the eﬃcacy or safety of BaP
in CLL or BNHL can be drawn due to only 1 patient being recruited in
each cohort. BaP therapy is not a competitive option in CLL at this time
given the new drugs that have recently become available to these pa-
tients [5]. Generically BaP is not attractive in BNHL at this time.
However, given the eﬃcacy seen in children with endemic Burkitt's
lymphoma [3] and the lack of eﬀective regimens for relapsed and re-
fractory sporadic Burkett's lymphoma there is cause to consider a pilot
study in this setting.
Since starting the BaP trial, a number of competing trials have de-
veloped in the AML setting in the UK. Due to this and the results of this
present study, it would appear that BaP based approaches in AML are
not currently viable. A further common challenge that has faced the two
BaP trials in AML has been the immediate poor prospects of the patients
entering the trials with most expected to deteriorate over the ﬁrst few
weeks. Despite this, the ﬁrst trial of low dose BaP saw signiﬁcant
haematological response in 4/11 evaluable patients for 22, 29, 30 and
201 weeks and no deterioration in haemopoiesis in the other 8 whilst
on BaP therapy. However, these eﬀects took greater than four weeks to
arise during which time many patients disease progressed signiﬁcantly.
Since the current therapeutic options in MDS are restricted it may be of
value to continue to evaluate a BaP based approach in this setting ra-
ther than AML. Furthermore, screening of low dose BaP against libraries
of other already available dugs may identify a more eﬃcacious com-
bination with increased anti-neoplastic eﬀect and little or no increased
toxicity.
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